Abughosh, Susan M.2015-08-252015-08-25August 2012013-08http://hdl.handle.net/10657/1070Objective I: To compare the continuous abstinence rates of FDA-approved smoking cessation medication strategies during a) 3 months, b) 6 months, and b) 12 months follow up period among obese smokers. Hypothesis (Ha): Abstinence rates among obese smokers using varenicline will be higher compared to obese smokers using bupropion during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective II: To compare the post-cessation weight gain between the two FDA-approved smoking cessation medications during: a) 3 months, b) 6 months, and c) 12 months of follow up period. Hypothesis (Ha): Obese smokers using bupropion experience lesser weight gain compared to those obese smokers using varenicline during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective III: To compare the risk of developing diabetes following smoking cessation during the first year follow up among obese smokers between the FDA-approved smoking cessation medications (bupropion and varenicline). Hypothesis (Ha): Obese smokers using bupropion are less likely to develop diabetes following smoking cessation during a 1-year follow up compared to those using varenicline.application/pdfengThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).Comparative effectivenessSmoking cessationAbstinence rateObesityWeight ChangeType 2 DiabetesVareniclineBupropionPharmacy management2015-08-25Thesisborn digital